Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial

Frille, Armin; Hardavella, Georgia; Lee, Richard

doi:10.1183/20734735.0322-2019

Cited by 13 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall detection rate of lung cancer in this study was 1.8%, which was higher than those in the NLST (1.1%) (36) and NELSON (0.9%) (6) studies, with age and smoking history as inclusion criteria. However, it was similar to screening studies of non-smoking women (10,13,37).…”

Section: Discussioncontrasting

confidence: 65%

Low-dose computed tomography for lung cancer screening in Anhui, China: A randomized controlled trial

Ren

Shi

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundLung cancer is the leading cause of cancer-related death worldwide, with risk factors such as age and smoking. Low-dose computed tomography screening can reduce lung cancer mortality. However, its effectiveness in Asian populations remains unclear. Most Asian women with lung cancer are non-smokers who have not been screened. We conducted a randomized controlled trial to evaluate the performance of low-dose computed tomography screening in a Chinese population, including high-risk smokers and non-smokers exposed to passive smoking. The baseline data are reported in this study.MethodsBetween May and December 2019, eligible participants were randomized in a ratio of 1:1:1 to a screening (two arms) or control cohort. Non-calcified nodules/masses with a diameter >4 mm on low-dose computed tomography were considered positive findings.ResultsIn total, 600 patients (mean age, 59.1 ± 6.9 years) underwent low-dose computed tomography. Women accounted for 31.5% (189/600) of patients; 89.9% (170/189) were non-smokers/passive smokers. At baseline, the incidence of lung cancer was 1.8% (11/600). The incidence of lung cancer was significantly lower in smokers than in female non-smokers/passive smokers (1.0% [4/415] vs. 4.1% [7/170], respectively; P=0.017). Stage 0–I lung cancer accounted for 90.9% (10/11) of cases.ConclusionsWe demonstrate the importance of including active smokers and female non-smokers/passive smokers in lung cancer screening programs. Further studies are needed to explore the risk factors, and long-term cost–benefit of screening Asian non-smoking women.Clinical trial registrationhttp://chictr.org.cn/showproj.aspx?proj=39003, identifier ChiCTR1900023197.

show abstract

Section: Discussioncontrasting

confidence: 65%

Low-dose computed tomography for lung cancer screening in Anhui, China: A randomized controlled trial

Ren

Shi

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Current evidence suggests that the 5-year survival rate of patients with early or intermediate-stage lung cancer (more than 70%) is significantly higher than late-stage lung cancer (less than 15%) (4). Therefore, early screening, diagnosis and treatment of lung cancer can significantly improve patient survival and prognosis (1,(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

“…In clinical practice, low-dose computed tomography (LDCT), positron emission tomography/computed tomography (PET/CT) and tumor biomarkers are commonly used to screen solitary pulmonary nodules (SPNs) (4,(7)(8)(9)(10). It has been reported that the false positive rate of high-resolution computed tomography (HRCT) is 96.4% (4), which makes it difficult to ascertain the nature of pulmonary lesions.…”

Section: Introductionmentioning

confidence: 99%

EB-OCT: a potential strategy on early diagnosis and treatment for lung cancer

Long

Chen

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related death in China and the world, mainly attributed to delayed diagnosis, given that currently available early screening strategies exhibit limited value. Endobronchial optical coherence tomography (EB-OCT) has the characteristics of non-invasiveness, accuracy, and repeatability. Importantly, the combination of EB-OCT with existing technologies represents a potential approach for early screening and diagnosis. In this review, we introduce the structure and strengths of EB-OCT. Furthermore, we provide a comprehensive overview of the application of EB-OCT on early screening and diagnosis of lung cancer from in vivo experiments to clinical studies, including differential diagnosis of airway lesions, early screening for lung cancer, lung nodules, lymph node biopsy and localization and palliative treatment of lung cancer. Moreover, the bottlenecks and difficulties in developing and popularizing EB-OCT for diagnosis and treatment during clinical practice are analyzed. The characteristics of OCT images of normal and cancerous lung tissues were in good agreement with the results of pathology, which could be used to judge the nature of lung lesions in real time. In addition, EB-OCT can be used as an assistant to biopsy of pulmonary nodules and improve the success rate of biopsy. EB-OCT also plays an auxiliary role in the treatment of lung cancer. In conclusion, EB-OCT is non-invasive, safe and accurate in real-time. It is of great significance in the diagnosis of lung cancer and suitable for clinical application and is expected to become an important diagnostic method for lung cancer in the future.

show abstract

“…Metastasis in lung cancer is the major reason leading to mortality of lung cancer patients. Although the application of the Lung Screening Trial (low dose helical computed tomography, LDCT) with chest radiography allows lung cancer to be diagnosed at an early stage, the prognosis of metastatic lung cancer is still unpromising even if combining surgery with radiotherapy, chemotherapy, immunotherapy and gene-targeted drug therapy [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Overexpression of CXCR7 accelerates tumor growth and metastasis of lung cancer cells

Liu

Qian

et al. 2020

Respir Res

View full text Add to dashboard Cite

Background Under physiological conditions, CXCL12 modulates cell proliferation, survival, angiogenesis, and migration mainly through CXCR4. Interestingly, the newly discovered receptor CXCR7 for CXCL12 is highly expressed in many tumor cells as well as tumor-associated blood vessels, although the level of CXCR7 in normal cells is low. Recently, many studies have suggested that CXCR7 promotes cell growth and metastasis in more than 20 human malignancies, among which lung cancer is the leading cause of cancer-associated deaths worldwide. Thus, the mechanism of CXCR7 in the progression of lung cancer is urgently needed. Methods First, we explored CXCR4 and CXCR7 expression in human lung cancer specimens and cell lines by immunohistochemistry, western blot and flow cytometry. Then, we chose the human lung adenocarcinoma cell line A549 that stably overexpressed CXCR7 through the way of lentivirus-mediated transduction. Next, “wound healing” assay and transwell assay were applied to compare the cell migration and invasion ability, and stripe assay was used to evaluate the cell polarization. Last, our team established a mouse xenograft model of human lung cancer and monitored tumor proliferation and metastasis by firefly luciferase bioluminescence imaging in SCID/Beige mice. Results In clinical lung cancer samples, CXCR7 expression was almost not detected in normal tissue but upregulated in lung tumor tissue, whereas, CXCR4 was highly expressed in both normal and tumor tissues. Furthermore, overexpression of CXCR7 enhanced A549 cell migration and polarization in vitro. Besides, mouse xenograft model of human lung cancer showed that CXCR7 promoted primary lung tumor’s growth and metastasis to the second organ, such as liver or bone marrow in SCID/Beige mice in vivo. Conclusions This study describes the multiple functions of CXCR7 in lung cancer. Thus, these results suggest that CXCR7 may be a malignancy marker and may provide a novel target for anticancer therapy.

show abstract

Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial

Abstract: @ERSpublicationsThe extended follow-up of the NLST represents a timely and important update to the NLST data, alongside full results of the NELSON and the LUSI trials, as Europe begins to set out a vision for lung cancer screening. http://bit.ly/2MYXedI Affiliations

Cited by 13 publications

References 10 publications

Low-dose computed tomography for lung cancer screening in Anhui, China: A randomized controlled trial

Low-dose computed tomography for lung cancer screening in Anhui, China: A randomized controlled trial

EB-OCT: a potential strategy on early diagnosis and treatment for lung cancer

Overexpression of CXCR7 accelerates tumor growth and metastasis of lung cancer cells

Contact Info

Product

Resources

About